Artelo Biosciences financials
$4.07−5.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Aug 31 | FY20 Aug 31 | FY19 Aug 31 | FY18 Aug 31 | FY17 Aug 31 | FY16 Aug 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$7.4M | -$4.7M | -$3.2M | -$2.3M | -$232.8K | -$29.7K |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$7.4M | -$4.7M | -$2.2M | -$2.3M | -$234.9K | -$29.7K |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-338.04 | $-494.10 | $-508.68 | $-576.72 | $-972.00 | $-3061.80 | $-2430.00 | $-4471.20 | $-583.20 | $0.00 |
| EBITDA | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$7.4M | -$4.7M | -$3.2M | -$2.3M | -$232.8K | -$29.7K |
| Operating cash flow | -$8.5M | -$8.3M | -$8.2M | -$8.0M | -$6.1M | -$4.3M | -$2.8M | -$1.6M | -$216.8K | -$18.5K |
| Free cash flow | -$8.8M | -$8.3M | -$8.2M | -$8.0M | — | — | -$2.8M | -$1.6M | — | — |
| Diluted shares | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Aug 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $600.0K | $2.3M | $2.8M | $6.9M | $12.2M | $2.1M |
| Short-term investments | $0.00 | $0.00 | $7.6M | $10.6M | $12.0M | $0.00 |
| Total debt | $437.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $28.3M | $4.4M |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $1.1M | $501.0K |
| Shareholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $27.2M | $3.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology